Adverum Biotechnologies to Present at the 2018 Jefferies Global Healthcare Conference

MENLO PARK, Calif., June 04, 2018 (GLOBE NEWSWIRE) — Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases, announced today that Leone Patterson, interim president and chief executive officer of Adverum, will present at the Jefferies Global Healthcare Conference.

A live and replay audio webcast of the presentation will be available from Adverum’s website at http://investors.adverum.com.

About Adverum Biotechnologies, Inc.
Adverum is a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases. Adverum has a robust pipeline that includes product candidates designed to treat rare diseases alpha-1 antitrypsin (A1AT) deficiency and hereditary angioedema (HAE) as well as wet age-related macular degeneration (wAMD). Leveraging a next-generation adeno-associated virus (AAV)-based directed evolution platform, Adverum generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum has collaboration agreements with Regeneron Pharmaceuticals to research, develop, and commercialize gene therapy products for ophthalmic diseases and Editas Medicine to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases. Adverum’s core capabilities include clinical development and in-house manufacturing expertise, specifically in process development and assay development. For more information please visit www.adverum.com.

Adverum Contact:
Leone Patterson
Interim President and Chief Executive Officer
650-665-7222
lpatterson@adverum.com

Source: Adverum Biotechnologies, Inc.